| First Author | Zhang Y | Year | 2016 |
| Journal | Oncotarget | Volume | 7 |
| Issue | 11 | Pages | 12010-23 |
| PubMed ID | 26910838 | Mgi Jnum | J:309235 |
| Mgi Id | MGI:6757407 | Doi | 10.18632/oncotarget.7505 |
| Citation | Zhang Y, et al. (2016) CD226 reduces endothelial cell glucose uptake under hyperglycemic conditions with inflammation in type 2 diabetes mellitus. Oncotarget 7(11):12010-23 |
| abstractText | CD226 is a co-stimulatory adhesion molecule found on immune and endothelial cells. Here, we evaluated a possible role for CD226 in inhibiting glucose uptake in isolated human umbilical vein endothelial cells (HUVECs) and in wild-type (WT) and CD226 knockout (KO) mice with high-fat diet (HFD)-induced type 2 diabetes (T2DM). CD226 expression increased under hyperglycemic conditions in the presence of TNF-alpha. Furthermore, CD226 knockdown improved glucose uptake in endothelial cells, and CD226 KO mice exhibited increased glucose tolerance. Levels of soluble CD226 in plasma were higher in T2DM patients following an oral glucose tolerance test (OGTT) than under fasting conditions. Our results indicate that low-grade inflammation coupled with elevated blood glucose increases CD226 expression, resulting in decreased endothelial cell glucose uptake in T2DM. |
